doi: 10.1001/jama.2024.18219.
GLP-1 Medication Use for Type 2 Diabetes Has Soared
Affiliations
- PMID: 39212980
- DOI: 10.1001/jama.2024.18219
Item in Clipboard
GLP-1 Medication Use for Type 2 Diabetes Has Soared
JAMA.
.
No abstract available
Plain language summary
This JAMA Data Brief discusses new data from the Medical Expenditure Panel Survey, or MEPS, Household Component, a household survey sponsored by the Agency for Healthcare Research and Quality.
Similar articles
-
Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable.JAMA. 2024 Jul 2;332(1):8. doi: 10.1001/jama.2024.10333. JAMA. 2024. PMID: 38848082 No abstract available.
-
State Coverage and Reimbursement of Antiobesity Medications in Medicaid.JAMA. 2024 Apr 9;331(14):1230-1232. doi: 10.1001/jama.2024.3073. JAMA. 2024. PMID: 38483403 Free PMC article.
-
Medicaid, family spending, and the financial implications of crowd-out.J Health Econ. 2017 May;53:1-16. doi: 10.1016/j.jhealeco.2017.02.002. Epub 2017 Feb 16. J Health Econ. 2017. PMID: 28242432
-
International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches.Lancet. 2024 Aug 31;404(10455):902-906. doi: 10.1016/S0140-6736(24)01356-4. Epub 2024 Aug 16. Lancet. 2024. PMID: 39159651 Review. No abstract available.
-
Children's Coverage Vulnerabilities With Loss of a Parent's Employer-Sponsored Insurance.Pediatrics. 2021 Feb;147(2):e2020032730. doi: 10.1542/peds.2020-032730. Epub 2021 Jan 14. Pediatrics. 2021. PMID: 33446507 Review. No abstract available.
Cited by
-
Ivonescimab: First Approval.Drugs. 2024 Sep;84(9):1135-1142. doi: 10.1007/s40265-024-02073-w. Epub 2024 Jul 29. Drugs. 2024. PMID: 39073550 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
